Artiva Biotherapeutics, Inc. to outline AlloNK Phase 3 progress at New York Jefferies event

Artiva Biotherapeutics, Inc. to outline AlloNK Phase 3 progress at New York Jefferies event
Artiva CEO to speak at Jefferies

Artiva Biotherapeutics, Inc. will participate in the 2026 Jefferies Global Healthcare Conference in New York, with CEO Fred Aslan, M.D., slated for a fireside chat on Thursday, June 4, from 9:20 a.m. to 9:50 a.m. EDT.

The event takes place as Artiva Biotherapeutics, Inc. progresses its AlloNK program toward the first Phase 3 clinical trial, potentially marking a significant milestone for the company's pipeline in cellular immunotherapy. Industry participants are likely to watch for updates on the development strategy and expected timelines for the Phase 3 launch.

Artiva recently reported initial positive results for AlloNK and announced plans to advance to a Phase 3 trial in rheumatoid arthritis in 2026. The company is also scheduled to present five abstracts on AlloNK data for autoimmune diseases at EULAR 2026. These developments come as Artiva builds momentum in its cellular immunotherapy pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.